Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE follow-on study of AR101 maintenance dosing in peanut allergy
NL-OMON48551Phase 3Active, not recruiting
- Sponsor
- Aimmune Therapeutics
- Start
- Sep 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of peanut protein in peanut allergy (2 arms), sponsored by Aimmune Therapeutics. Started Sep 2017; status: active, not recruiting.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NL-OMON48551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48551.